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PURPOSE: The monocyte-to-lymphocyte ratio (MLR) hasbeenshown tobeassociatedwith theprognosis of various solid
tumors. This study sought to evaluate the important value of the MLR in ovarian cancer patients.METHODS: A total of 133
ovarian cancer patients and 43 normal controls were retrospectively reviewed. The patients' demographics were analyzed
along with clinical and pathologic data. The counts of peripheral neutrophils, lymphocytes, monocytes, and platelets were
collected and used to calculate the MLR, neutrophil-to-lymphocyte ratio (NLR). and platelet-to-lymphocyte ratio (PLR). The
optimal cutoff value of theMLRwas determined by using receiver operating characteristic curve analysis.We compared the
MLR, NLR, and PLR between ovarian cancer and normal control patients and among patients with different stages and
different grades, as well as between patients with lymph node metastasis and non–lymph node metastasis. We then
investigated the value of the MLR in predicting the stage, grade, and lymph node positivity by using logistic regression. The
impact of theMLRon overall survival (OS)was calculated by Kaplan-Meiermethod and compared by log-rank test.RESULTS:
Statistically significant differences in theMLRwere observed betweenovarian cancer patients andnormal controls. However,
no difference was found for the NLR and PLR. Highly significant differences in the MLR were found among patients with
different stages (stage I-II and stage III-IV), grades (G1 andNG1), and lymphnodemetastasis status. TheMLRwasa significant
and independent risk factor for lymph nodemetastasis, as determined by logistic regression. The optimal cutoff value of the
MLRwas0.23.Wealso classified the data according to tumormarkers (CA125, CA199,HE4, AFP, andCEA) and conventional
coagulation parameters (International Normalized Ratio [INR] and fibrinogen). Highly significant differences in CA125, CA199,
HE4, INR, fibrinogen levels, and lactate dehydrogenasewere found between the low-MLR group (MLR≤ 0.23) and the
high-MLR group (MLR N 0.23). Correspondingly, dramatic differences were observed between the two groups in OS.
CONCLUSION:Our results show that theperipheral bloodMLRbefore surgery couldbea significant predictor of advanced
stages, advanced pathologic grades, and positive lymphatic metastasis in ovarian cancer patients.
Translational Oncology (2016) 10, 33–39(no. 11QA1405200, Y.-Y. He), and Nature Science Foundation of Shanghai
(no. 13ZR1459600, L.-N. Zhou).
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Table 1. The Clinical Baseline Characteristics of Ovarian Patients
Variable No. of Patients (%)
Age (years, mean ± SD) 53.27 ± 13.57 (20-82)
Histological type, n (%) 133 (100%)
Serous 87 (65.41%)
Mucinous 14 (10.53%)
Endometrioid 10 (7.52%)
Clear cell 5 (3.76%)
Others 17 (12.78%)
Differentiation, n (%) 133 (100%)
G1 24 (18.04%)
G2 52 (39.10%)
G3 57 (42.86%)
Stage, n (%) 133 (100%)
I 37 (27.82%)
II 27 (20.30%)
III 65 (48.87%)
IV 4 (3.01%)
Lymphatic metastasis, n (%) 133 (100%)
Negative 111 (83.46%)
Positive 22 (16.54%)
Optimal debulking, n (%) 133 (100%)
No 6 (4.51%)
Yes 127 (95.49%)
Others: including immature teratoma (three cases), granulosa cell tumor (three cases), endodermal sinus
tumor (three cases), undifferentiated tumor (three cases), carcinoid tumor (three case), squamous cell carcinoma
(two case).
Table 2. Clinical and Test Characteristics of Ovarian Cancer Population
Variable Mean ± SD
CA-125 (U/ml) 1092.36 ± 94.53
CA-199(U/ml) 72.89 ± 16.27
AFP (ng/ml) 16.95 ± 4.49
CEA(ng/ml) 8.29 ± 2.70
HE4 (pmol/l) 455.57 ± 39.47
WBC ( 109/l) 6.59 ± 3.20
N (%) 67.63 ± 11.59
L (%) 24.37 ± 10.04
M (%) 6.04 ± 2.55
Hemoglobin (g/l) 119.87 ± 17.94
Platelet ( 109/l) 279.57 ± 112.24
Ln NLR 1.07 ± 0.59
Ln MLR -1.45 ± 0.52
Ln PLR 5.22 ± 0.57
D-Dimer (mg/l) 2.43 ± 1.01
PT (s) 11.69 ± 1.39
INR 0.99 ± 0.09
APTT (s) 27.03 ± 4.00
TT (s) 18.43 ± 2.69
Fibrinogen, FIG (mg/l) 3.49 ± 1.06
LDH (U/l) 196.64 ± 88.8
Detected after 2013.
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Ovarian cancer is the most lethal gynecologic cancer and one of the
most important causes of cancer-related deaths in women worldwide
[1]. Fewer than half of patients survive for more than 5 years after
diagnosis. More than 75% of patients are diagnosed at an advanced
stage after menopause because early-stage disease is usually
asymptomatic, and the symptoms of late-stage disease are nonspecific
[2]. Given the poor prognosis of ovarian cancer, a method
for accurately predicting the prognosis of patients with ovarian
cancer after curative surgical resection is necessary to improve patient
survival [3,4].
Owing to increasing evidence regarding the role of inflammation in
cancer biology, a systemic inflammatory response has been found to
have prognostic significance in a variety of cancers. Kawata et al. have
reported that lymphocyte infiltration around the tumor is associated
with a better prognosis in HCC [5], whereas the presence of
neutrophils in the tumor stroma is associated with a poor prognosis
[6]. Likewise, the neutrophil-to-lymphocyte ratio (NLR), a predictor
of inflammatory status, has been shown to be an effective prognostic
marker for many solid tumors [7–13]. In addition to neutrophils and
lymphocytes, monocytes are another important type of leucocyte.
Studies have shown that monocytes are an independent prognostic
factor, and a higher number of monocytes predict a poor prognosis,
similar to the role of neutrophils in predicting prognosis. The
monocyte-to-lymphocyte ratio (MLR), i.e., the monocyte count
divided by the lymphocyte count, has recently been shown to be a
much more efficient prognostic predictor in many solid tumors.
The purpose of this study was to evaluate the MLR's
interindividual differences and its diagnostic efficiency, feasibility,
and predictive value for patients with ovarian cancer.
Materials and Methods
This retrospective analysis was conducted by using the clinical data
obtained from ovarian cancer patients who underwent surgical
resection at the Department of Obstetrics and Gynecology, Shanghai
General Hospital, Shanghai Jiaotong University School of Medicine,
between January 2011 and March 2016. The study was reviewed and
approved by the Institutional Review Board and the Research Ethics
Committee of Shanghai First People's Hospital. All participants gave
informed consent to participate in the study.
The cases of 133 ovarian cancer patients and 43 normal controls
were retrospectively reviewed. The clinical stage of ovarian cancer was
determined according to the International Federation of Gynecology
and Obstetrics (FIGO) stage. The selection criteria for patients were
as follows: 1) ovarian cancer confirmed by pathology; 2) no
preoperative treatments, such as radiotherapy or neoadjuvant
chemotherapy; 3) no coexisting cancers or prior cancers within the
previous 5 years; 4) complete clinical, laboratory, imaging, and
follow-up data; 5) no evidence of sepsis [7]; 6) no autoimmune
disease or treatment with steroids; and 7) no hematological disorders
or treatment that could result in an elevated MLR or NLR, for
example, the administration of hematopoietic agents, such as
granulocyte colony-stimulating factor, within 1 month before
surgery. Routine blood tests, routine coagulation tests, and
measurements of tumor markers (CA125, CA199, HE4, AFP, and
CEA) were performed on the day before surgery. The normal controls
are the healthy women aged 35 to 60 years. The MLR, NLR, and
platelet-to-lymphocyte ratio (PLR) were defined as the ratio of the
absolute peripheral blood monocyte and lymphocyte counts, absoluteneutrophil and lymphocyte counts, and absolute platelet and lymphocyte
counts, respectively.
Data, including information on patient demographics, were
collected for analysis. The clinicopathologic variables, including age,
FIGO stage, histologic grade, lymph node metastasis, and CA-125
levels, were obtained retrospectively from patient medical records.
Each cytoreduction was principally aimed at maximal tumor resection
without a visible residual tumor. If technically achievable, all visible
cancer was resected to achieve optimal tumor debulking, leaving a
residual tumor with a maximal diameter of ≤1 cm [40].
We determined the optimized MLR cutoff values for predicting
survival outcomes using receiver operating characteristic (ROC) curve
analysis, and the best MLR cutoff value for diagnosis was 0.23.
Patients were grouped according to the results of the ROC curve
Figure 1. High MLR in ovarian cancer patients.(A, B, and C) The Ln MLR, Ln NLR, and Ln PLR between the control group and the ovarian
cancer group, respectively. **P = .0003; *P = .039; P N .05.
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0.23). Differences in cancer- and host-related risk factors, including
age, FIGO stage, histologic grade, optimal debulking (OD), serum
CA-125 levels and overall survival (OS), between the MLR-low and
MLR-high groups were analyzed.
Statistical Analysis
All statistical analyses were performed with SPSS version 19.0
software (Chicago, IL). After logarithmic transformations of the
MLR, NLR, and PLR, the log-transformed data were close to a
normal distribution. Therefore, we used the log-transformed data for
statistical analysis. t tests and one-way analysis of variance (ANOVA)
were used to analyze the data of two independent groups or three and
four groups, respectively. To account for their effects on the
relationships between the MLR and the stages, histological types,
grades, lymphatic metastasis, and OD, all variables were included in a
binary logistic regression analysis. The OS was assessed using the
Kaplan-Meier method and compared by log-rank test. A P value of b .05
was considered to be statistically significant.
Results
The Clinical Baseline Characteristics of Ovarian Cancer Patients
The baseline characteristics of the patients are displayed in Table 1.
Serous adenocarcinoma was the most common subtype (65.41%),
and histological grade 3 was the most frequent grade (42.86%) in our
cohort. In total, 37 (27.82%), 27 (20.30%), 65 (48.87%), and 4
(3.01%) patients had stage I, II, III, and IV disease, respectively.Additionally, 22 (16.54%) patients had lymphatic metastasis. OD
was performed in 127 (95.49%) patients.
The Hematological Baseline Characteristics of Ovarian
Cancer Patients
The median neutrophil, monocyte, and platelet counts were
67.63 × 10^9/l, 6.04 × 10^9/l, and 24.37 × 10^9/l, respectively. The
NLR, MLR, and PLR were 3.73, 0.30, and 225.96, respectively.
The values for the coagulation system factor, D-dimer, prothrombin
time (PT), International Normalized Ratio (INR), activated partial
thromboplastin time (APTT), thrombin time (TT), and fibrinogen
were 2.43, 11.69, 0.99, 27.03, 18.43, and 3.49, respectively. (Table 2).
The median serum levels of the tumor markers CA125, CA199, AFP,
CEA, andHE4 were 1092.36 U/ml, 72.89 U/ml, 16.95 U/ml, 8.29 U/ml,
and 455.57 U/ml, respectively.
MLR, NLR, and PLR between Ovarian Cancer Patients
and Controls
When we compared the MLR and PLR between ovarian cancer
patients and controls, significant differences were observed (P = .0003 and
P = .046). However, no differences in the NLR were found between
ovarian cancer patients and normal controls (P = .304) (Figure 1).
MLR as an independent Predictor of Ovarian Cancer and Is
Positively Correlated with CA125
Given that the MLR was different between the control group and
ovarian cancer group, we sought to determine whether the MLR
could be a predictor of ovarian cancer. In the binary logistic
Table 3. Independent Predictors of Ovarian Cancer in the Binary Logistic Regression Analysis
β P OR 95% CI (OR)
MLR 2.14 .00 8.50 2.65-27.71
NLR −1.49 .02 0.23 0.07-0.79
PLR 0.689 .20 1.92 0.70-5.64
All analyzed data were Ln (original data) transformed from the original data and tested with binary
logistic regression.
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risk factor of ovarian cancer [odds ratio (OR) = 8.50, 95% confidence
interval (CI) = 2.65-27.71] (Table 3).
Then, we examined the ROC curve of the MLR in distinguishing
the control from ovarian cancer patients. In the ROC analysis, the
area under the curve is 0.68 (95% CI, 0.59-0.76). A cutoff of 0.23
was identified to reach a sensitivity of 50% and a specificity of 90%
from this study cohort (Figure 2).
Because CA125 is an important maker of ovarian cancer, we next
investigated the relationship with MLR by Spearman's rank
correlation analysis using original data of MLR and CA125.
There was a significant positive correlation between MLR and CA125
(r = 0.46, P = .00).
The Differences in the MLR across Stages, Histological Types,
Grades, Lymphatic Metastasis, and OD
Next, we investigated differences in the MLR with respect to
histological types, grades, stages, lymphatic metastasis, and OD. As
shown in Figure 3, significant differences were found for categorical
variables including FIGO stages (P b .0001), histological grades (P = .0076),
and lymphatic metastasis (P = .0004), but not including histological
types (P = .4034) and OD (P = .1056).
The MLR was an independent risk factor for advanced stages,
lymphatic metastasis, and advanced pathological grades in ovarian
cancer patients.
Because the MLR was significantly different among patients with
different FIGO stages, lymphatic metastasis, and tumor pathological
grades, we further investigated the association between the MLR withFigure 2. Diagnostic accuracy of the MLR for the prediction of
ovarian cancer.*ROC analysis of the control group MLR and the
ovarian cancer group MLR.AUC, area under curve.the stages, lymphatic metastasis, and grades by using binary logistic
regression. As shown in Table 4, the MLR was significantly associated
with stages, lymphatic metastasis, and grades. All of the three β values
and OR values were N1, indicating that the MLR was a significant
independent risk factor for advanced stages, lymphatic metastasis, and
advanced grades.
Initially, we assessed differences in the MLR in three pathologic
grades by using one-way ANOVA. We found that the MLR was
significantly different between G1 and G2 and between G1 and G3.
However, no significant differences were observed between G2 andG3.
Therefore, wemerged the data ofG2 andG3 into one group, the “NG1”
group, and reanalyzed the data with the results shown in Figure 3B.
Furthermore, logistic regression was performed and showed that the
grade is associated with MLR (P = .01, β = 1.32, OR = 3.72).
Differences in the Baseline Characteristics between the
MLR-Low and MLR-High Groups
The optimal cutoff value of the MLR was 0.23 (Figure 2). The
MLR-low and MLR-high groups included 64 (48.12%) and 69
(51.88%) patients, respectively. To evaluate the relevance of the
MLR, we assessed differences in the baseline characteristics of the
patients according to the different MLR categories. Significant
differences between the MLR-low and MLR-high groups were found
for the following continuous variables: serum CA125 levels (P =
.000), serum CA199 levels (P = .033), HE4 levels (P = .005),
percentage of neutrophils (P = .000), percentage of lymphocytes (P =
.000), percentage of monocytes (P = .000), NLR (P = .000), MLR
(P = .000), PLR (P = .000), INR (P = .000), fibrinogen (P = .000),
and lactate dehydrogenase (P = .016) (Table 5).
MLR Predicted OS in 124 Patients with Ovarian Cancer
After a median follow-up of 23.617 months (range, 0.767-69.4
months), there were 6 patients who died in the MLR-low group, and
there were 14 patients who died in the MLR-high group. The total
missed follow-up rate was 6.767%. Based on Kaplan-Meier analysis,
high MLR was significantly associated with a lower OS rate and
higher mortality in ovarian cancer (P = .037) (Figure 4).Discussion
Ovarian cancer is the most lethal gynecologic cancer and is one of the
major causes of cancer-related death in women worldwide. The high
mortality is partly due to difficulties in early diagnosis and the
development ofmetastases. Given this cancer's poor prognosis,methods
for accurately predicting risk factors that affect cancer severity and early
diagnosis are required to improve patient survival rates.
In recent years, several prognostic indicators derived from peripheral
blood, such as theMLR,NLR, and PLR, have beenwidely investigated as
useful prognostic markers in cancers. Despite inconsistent results, these
markers have been reported to have significant diagnostic and prognostic
value in a wide variety of cancers. The MLR has been suggested to be
associated with survival in patients with malignant lymphomas andmany
solid tumors, such as head and neck, breast [14], lung, esophageal, gastric,
colorectal [15,16], pancreatic, bladder [6], and cervical cancers [5]. A high
MLRwas associated with poor OS in previous reports, and theMLR can
be considered to be a potential surrogate biomarker in various cancers.
Although themechanisms of the association between a higherMLR and a
poorer prognosis have not been fully clarified, the MLR may reflect the
balance between the favorable role of lymphocytes and the unfavorable
effect of monocytes with respect to cancer progression.
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cancer group than in the control group. The higher MLR indicated
lower lymphocyte or higher monocyte levels in the peripheral blood
of ovarian cancer patients. Lymphocytes play important roles in the
defense against cancer cells by inducing cytotoxic cell death and
suppressing tumor cell proliferation and migration. Many types of
lymphocytes, such as T cells, dendritic cells, monocytes, and
macrophages, have been shown to infiltrate ovarian cancer [17–23].
It is well accepted that tumor-infiltrating lymphocytes establish a
defense barrier against cancer dissemination. Therefore, decreased
lymphocyte counts in the blood and tumor stroma lead to a
downregulation of the immune response against tumors [5].
Moreover, a decreased lymphocyte count in the blood has been
identified as an independent prognostic factor for OS in various
cancers. Additionally, the pretreatment number of peripheral blood
monocytes has been shown to be correlated with poor prognosis in
patients with various types of cancers. After recruitment into tumor
tissue, monocytes differentiate into tumor-associated macrophages
(TAMs) [22]. Evidence from clinical and experimental studies
has indicated that TAMs promote solid-tumor progression and
metastasis, and monocytes in the peripheral blood may reflect the
formation or presence of TAMs, which are a prominent componentFigure 3. Differences in the MLR among various stages, histolog
*P b .0001(t test); (B) *P = .0076 (t test); (C) P = .4034, one-way ANof the mononuclear leukocyte population of solid tumors and display
an ambivalent relationship with tumors. TAMs are educated by the
tumor microenvironment, and they facilitate angiogenesis, matrix
breakdown, and tumor-cell motility, all of which are elements of the
metastatic process. During an inflammatory response, macrophages
also produce many compounds, ranging from mutagenic oxygen and
nitrogen radicals to angiogenic factors that can contribute to cancer
initiation and promotion. As such, monocytes/TAMs can promote
solid-tumor progression and metastasis [24–26]. Furthermore,
ovarian cancer also has the ability to escape the immune system
because pathological interactions between cancer cells and host
immune cells in the tumor microenvironment create an immuno-
suppressive network that promotes tumor growth and protects the
tumor from the immune system [24,25]. Therefore, we speculated
that the higher MLR of ovarian cancer patients may indicate increased
monocyte differentiation and infiltration of TAMs, which are
involved in ovarian cancer cell immune escape, thereby stimulating
ovarian cancer progression and metastasis. However, this possibility
requires further study.
Our results also showed, via logistic regression, that a higher MLR
was observed in patients with a higher stage and grade, as well as those
with positive lymphatic metastasis, and is therefore an independentical types, pathologic grades, lymphatic metastasis, and OD.(A)
OVA; (D) P = .0004 (t test); (E) P = .1056; one-way ANOVA.
Table 4. Logistic Regression Estimates (β Coefficients and 95% CI) of the Association between
MLR and Stages, Lymphatic Metastasis, and Histological Grades
β P OR 95% CI (OR)
Stages 1.15 .002 3.15 1.55-6.44
Lymphatic metastasis 1.55 .000 4.70 1.880-11.74
Histological grades 1.32 .01 3.72 1.36-10.17
All analyzed data were Ln (original data) transformed from the original data and tested with binary
logistic regression. As in Figure 2, the stages were classified as stage I-II and stage III-IV, and β =
1.15 N 1, OR = 3.15 N 1, indicating that the MLR was a significant independent risk factor for
advanced stage in ovarian cancer patients. Similarly, the MLR was also a significantly important
predictor for lymphatic metastasis (β = 1.55 N 1, OR = 4.70 N 1). The pathology grades were
divided into two groups, G1 and NG1 (G2 + G3), and tested with binary logistic regression. Because
β = 1.32 N 1 and OR = 3.72 N 1, the MLR was also shown to be a significant independent risk factor
of higher pathology grades.
Figure 4. Kaplan-Meier survival curves for OS in patients with
ovarian cancer.Significant differences were found between
MLR-low and MLR-high groups (P = .037).
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lymphatic metastasis. In most studies, the cutoff values for the MLR
were determined by ROC curve analysis. Our cutoff point of MLR
between normal and ovarian cancer was 0.23, also determined by
ROC curve analysis. In the present study, significant differences were
observed in the CA125, CA199, HE4, INR, fibrinogen levels, and
lactate dehydrogenase between the MLR-low (≤0.23) and MLR-high
(N0.23) groups (P b .0001). CA125 and CA199 are antibodies that
are considered to be ovarian cancer biomarkers, and malignant cancer
patients have hypercoagulation conditions with higher fibrinogen
levels. The association of MLR with cancer survival has been reported
for several cancers, such as bladder cancer, endometrial cancer, and
hepatocellular carcinoma [27–29]; however, it was rarely reported in
ovarian cancer. Our result revealed that lower MLR levels were
associated with favorable OS of ovarian cancer (P = .037). These
results were in accordance with other researches.
Unexpectedly, we found that the MLR was significantly associated
with coagulation conditions. It is well known that the hemostatic
components and the cancer biology are interconnected in multiple
ways. The hemostatic factors play a role in tumor progression. Cancer
cells are able to activate the coagulation system, release procoagulantTable 5. Clinical and Hematologic Characteristics of Ovarian Cancer Patients, according to the
Cutoff Value of the MLR
Variable MLR-Low (≤0.23) MLR-High (N0.23) P
Value
n Mean ± SD n Mean ± SD
Age (years) 64 49.81 ± 13.83 69 56.00 ± 12.60 .008
CA-125 (U/ml) 64 604.25 ± 1200.30 69 1557.93 ± 1790.81 .001
CA-199 (U/ml) 64 32.37 ± 84.37 69 113.41 ± 379.59 .108
AFP (ng/ml) 64 31.25 ± 171.52 69 2.87 ± 2.58 .205
CEA (ng/ml) 64 3.45 ± 10.23 69 13.21 ± 50.99 .151
HE4 (pmol/l) 38 240.84 ± 315.98 32 710.56 ± 867.76 .006
WBC ( 109/l) 64 5.99 ± 2.06 69 7.14 ± 3.96 .039
N (%) 64 62.57 ± 10.44 69 72.33 ± 10.79 .000
L (%) 64 30.53 ± 8.66 69 18.65 ± 7.73 .000
M (%) 64 4.93 ± 1.35 69 7.06 ± 2.97 .000
Hemoglobin (g/l) 64 124.42 ± 15.49 69 115.65 ± 19.33 .005
Platelet ( 109/l) 64 246.34 ± 89.99 69 310.39 ± 123.54 .001
D-Dimer (mg/l) 64 0.93 ± 0.82 69 3.70 ± 2.24 .001
PT (s) 64 11.54 ± 0.83 69 11.83 ± 1.78 .232
INR 64 0.97 ± 0.07 69 1.00 ± 0.11 .018
APTT (s) 64 26.51 ± 4.14 69 27.51 ± 3.86 .152
TT (s) 64 18.61 ± 2.28 69 18.25 ± 3.06 .445
Fibrinogen, FIG (mg/l) 64 3.08 ± 0.78 69 3.88 ± 1.16 .000
LDH (U/l) 64 180.60 ± 84.10 69 216.80 ± 84.88 .016
HE4 was detected after 2013.factor, microparticles that directly activate the coagulation cascade.
Our results suggested a close relationship between immune regulation
and hemostatic system, which may be involved in tumor progression.
But it needed further research.
From these data, we conclude that the MLR is involved in immune
escape and may reflect the immune regulation status of ovarian
cancer. When the MLR is increased, more monocytes/TAMs are
recruited and educated, more CA125 and CA199 are produced, and
increased coagulation is established, thus supporting an important
role of the MLR in ovarian cancer.
The strength of the current study is that it is the first attempt to evaluate
the predictive value of theMLR in ovarian cancer patients.Moreover, the
value of the MLR was evaluated together with previously validated
biomarkers, namely, theNLR and PLR. Some limitations were present in
this study, including its retrospective nature and the inclusion of a
relatively small number of patients. Another limitation is that theMLR is
a nonspecific marker of inflammation, and the results may be affected
by the presence of other systemic diseases. Additional large-scale and
standard investigations should be conducted to apply this convenient,
simple, and inexpensive prognostic factor for risk stratification.
Conclusion
This study was the first attempt to assess the predictive value of the
MLR in ovarian cancer patients. In this study, we found that an
elevated MLR reflected patient immune conditions and was a strong
risk factor for advanced ovarian cancer stages, pathologic grades,
lymphatic metastasis, and OS rate. Therefore, the MLR may be
clinically reliable and useful for the accurate prediction of ovarian
cancer initiation and subsequently for patient prognosis.
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